A Single-Center, Blinded, Placebo-Controlled Study Evaluating Cosmetic Efficacy and Safety of a Novel Topical GLPSGLT in Glucagon-Like Peptide-1 Analog-Treated Patients
Bibliographic record
Abstract
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are widely used for Type 2 diabetes and weight management but may adversely affect skin quality, resulting in dermal thinning, decreased elasticity, and accelerated aging—a phenomenon referred to as “GLP-1 Face.” A novel topical serum, GLPSGLT (Aforé LLC), was developed to counteract these effects using a proprietary blend of a bioavailable retinoic acid derivative, peptides, and botanical agents to support keratinocyte function and dermal repair. The authors of the study aim to evaluate the safety and efficacy of GLPSGLT serum in improving facial skin quality in patients undergoing GLP-1 RA or SGLT-2 therapy. In this split-face, double-blind pilot study, 7 female patients (median age 55) on stable GLP-1 RA/SGLT-2 therapy applied GLPSGLT serum to one side of the face and placebo to the other, twice daily for 6 weeks. Assessments at baseline, Day 21, and Day 42 included the Global Ranking Scale (GRS), standardized photography reviewed by a blinded physician, and a 26-item patient-satisfaction questionnaire. Treated sides showed statistically significant improvements across all 13 GRS domains vs placebo (P < .0001), particularly in hydration, surface roughness, pigmentation, vasculature, visible pores, and static wrinkles. The blinded reviewer correctly identified the treated side in all cases. Patients reported greater satisfaction with skin texture, firmness, radiance, and hydration. No adverse events were reported. GLPSGLT serum significantly improved skin quality in GLP-1 RA/SGLT-2-treated patients and was well-tolerated, warranting further investigation in larger, histologically assessed cohorts. Level of Evidence: 4 (Therapeutic)
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.003 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.001 | 0.002 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".